Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Ryosuke Hirabayashi"'
Autor:
Shota Takahashi, MD, Yuki Sato, MD, Yoshiharu Sato, PhD, Ryosuke Hirabayashi, MD, Shigeo Hara, MD, PhD, Yutaka Takahashi, MD, PhD, Keisuke Tomii, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 2, Pp 100639- (2024)
Histologic transformation is one of the mechanisms of resistance to EGFR tyrosine kinase inhibitor in patients with NSCLC with EGFR mutation. The transformation from adenocarcinoma to squamous cell carcinoma (SCC) has been recently recognized as a me
Externí odkaz:
https://doaj.org/article/1b4e2f74c1db4a6a897f9708f8f0ffaa
Autor:
Ryosuke Hirabayashi, Kazuma Nagata, Yuki Sato, Atsushi Nakagawa, Ryo Tachikawa, Hirokazu Kuroda, Ryutaro Seo, Takeshi Morimoto, Keisuke Tomii
Publikováno v:
BMC Pulmonary Medicine, Vol 23, Iss 1, Pp 1-10 (2023)
Abstract Background High-flow nasal cannula (HFNC) therapy is an important non-invasive respiratory support in acute respiratory failure, including coronavirus disease (COVID-19) pneumonia. Although the respiratory rate and oxygenation (ROX) index is
Externí odkaz:
https://doaj.org/article/38921cc1fd7a4c32a6e7e792b42b7446
Autor:
Takafumi Kabuto, Ryutaro Seo, Chisato Miyakoshi, Yuri Shimizu, Yusuke Shima, Daisuke Yamashita, Shigeo Hara, Ryosuke Hirabayashi, Keisuke Tomii, Masakazu Takayama, Keisuke Tetsumoto, Masao Saito, Hiroshi Hamakawa, Bela Suki, Yutaka Takahashi
Publikováno v:
PLoS ONE, Vol 18, Iss 3, p e0282868 (2023)
BackgroundBarotrauma frequently occurs in coronavirus disease 2019. Previous studies have reported barotrauma to be a mortality-risk factor; however, its time-dependent nature and pathophysiology are not elucidated. To investigate the time-dependent
Externí odkaz:
https://doaj.org/article/302a16e2c9b445c4a6fdbc97d01f9f55
Autor:
Yukari Satsuma, Hiroaki Ikesue, Kaori Kusuda, Mami Maeda, Nobuyuki Muroi, Ryobu Mori, Mariko Kogo, Ryosuke Hirabayashi, Kazuma Nagata, Atsushi Nakagawa, Ryo Tachikawa, Keisuke Tomii, Tohru Hashida
Publikováno v:
Frontiers in Pharmacology, Vol 11 (2020)
Background: Pirfenidone is an anti-fibrotic agent used to treat patients with idiopathic pulmonary fibrosis (IPF). Managing adverse drug events and ensuring compliance with pirfenidone treatment for a prolonged period are important to reduce the rate
Externí odkaz:
https://doaj.org/article/7b917075f63945708504f33124da4092
Publikováno v:
BMC Infectious Diseases, Vol 19, Iss 1, Pp 1-3 (2019)
Abstract Background Non-tuberculous mycobacteria cause chronic pulmonary infection, but pleuritis and pleural effusion are rarely associated with infection with non-tuberculous mycobacteria, especially rapid-growing mycobacteria. Case presentation A
Externí odkaz:
https://doaj.org/article/9c36e3a60fb144c9822cdb315dbab1d5
Autor:
Chigusa Shirakawa, Ryo Tachikawa, Ryohei Yamamoto, Chisato Miyakoshi, Kentaro Iwata, Kei Endo, Yuri Shimada, Yusuke Shima, Atsushi Matsunashi, Megumu Osaki, Ryosuke Hirabayashi, Yuki Sato, Kazuma Nagata, Atsushi Nakagawa, Keisuke Tomii
Publikováno v:
Respiratory Investigation. 61:321-331
Publikováno v:
Ceramics International. 49:9883-9892
Autor:
Yusuke Shima, Yuki Sato, Takeshi Morimoto, Shigeo Hara, Ryosuke Hirabayashi, Kazuma Nagata, Atsushi Nakagawa, Ryo Tachikawa, Hiroshi Hamakawa, Yutaka Takahashi, Keisuke Tomii
Publikováno v:
Investigational new drugs.
Objectives Postoperative recurrence in patients with non-small-cell lung carcinoma (NSCLC) is a major issue for life expectancy. Programmed cell death ligand 1 (PD-L1) expression on tumor cells is important in the prognosis of NSCLC. However, the pre
Autor:
Atsushi Nakagawa, Ryobu Mori, Kazuma Nagata, Ryosuke Hirabayashi, Nobuyuki Muroi, Tohru Hashida, Yukari Satsuma, Hiroaki Ikesue, Mami Maeda, Mariko Kogo, Ryo Tachikawa, Keisuke Tomii, Kaori Kusuda
Publikováno v:
Frontiers in Pharmacology
Frontiers in Pharmacology, Vol 11 (2020)
Frontiers in Pharmacology, Vol 11 (2020)
Background: Pirfenidone is an anti-fibrotic agent used to treat patients with idiopathic pulmonary fibrosis (IPF). Managing adverse drug events and ensuring compliance with pirfenidone treatment for a prolonged period are important to reduce the rate
Autor:
Kazuma Nagata, Yuki Sato, Yusuke Takahashi, Yusuke Shima, Ryosuke Hirabayashi, Yuri Shimada, Kyosuke Wakata, Atsushi Matsunashi, Kazutaka Hosoya, Megumu Osaki, Ryo Tachikawa, Atsushi Nakagawa, Keisuke Tomii
Publikováno v:
Rehabilitation and chronic care.